Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) FCF Margin (2020 - 2023)

Gain Therapeutics has reported FCF Margin over the past 4 years, most recently at 7663.03% for Q1 2023.

  • Quarterly results put FCF Margin at 7663.03% for Q1 2023, down 220772.0% from a year ago — trailing twelve months through Dec 2023 was 34217.53% (down 2364633.0% YoY), and the annual figure for FY2023 was 34217.53%, down 2364633.0%.
  • FCF Margin for Q1 2023 was 7663.03% at Gain Therapeutics, down from 5358.05% in the prior quarter.
  • Over the last five years, FCF Margin for GANX hit a ceiling of 3969.23% in Q2 2021 and a floor of 53869.71% in Q1 2021.
  • Median FCF Margin over the past 4 years was 8134.8% (2021), compared with a mean of 12697.39%.
  • Biggest five-year swings in FCF Margin: crashed -4251480bps in 2021 and later soared 4841440bps in 2022.
  • Gain Therapeutics' FCF Margin stood at 14473.88% in 2020, then rose by 21bps to 11440.14% in 2021, then surged by 53bps to 5358.05% in 2022, then plummeted by -43bps to 7663.03% in 2023.
  • The last three reported values for FCF Margin were 7663.03% (Q1 2023), 5358.05% (Q2 2022), and 5455.31% (Q1 2022) per Business Quant data.